Lupin Can't Escape Gilead's Ranexa Patent Suit

Law360, New York (March 8, 2013, 5:43 PM EST) -- A New Jersey federal judge on Thursday refused generic-drug maker Lupin Ltd.'s request to boot a patent infringement suit brought by Gilead Sciences Inc. over its chest pain drug Ranexa, rejecting Lupin’s contention that the claims raised were invalid.

U.S. District Judge Esther Salas denied Lupin's motion for summary judgment but details behind her decision and accompanying bench ruling were ordered sealed for 10 days, ensuring that claims in Gilead's 2010 suit seeking to protect nine patents it holds for the chronic angina treatment Ranexa can...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.